7 Insights on

• Absence of Adverse Effects
• No Treatment-Related Toxicity
• No Adverse Events Observed
• No Adverse Health Effects
• No Adverse Effects
• Absence of Significant Toxicity
• No Observed Adverse Effects

2 Insights on

• Gut Colonization by Saccharomyces boulardii
• Prevention of Candida albicans Gastrointestinal Colonization

8 Insights on

• Ensured Safety for Human Consumption
• Absence of Reproductive Toxicity
• Absence of Significant Toxicity
• Safe for Chronic Consumption
• No Observed Toxicity
• Reduced Chronic Consumption Toxicity
• Demonstrated Long-term Safety
• Absence of Toxicity

1 Insight on

• Reduced Fungal Growth

6 Insights on

• Enhanced Glycolysis Pathway Activation
• Increased Monocarboxylic Acid Transporter mRNAs
• Induced Glycolysis Pathway in Gastrointestinal Tract
• Increased Lactate Levels
• Modulation of Colon Epithelium by Lactate
• Increased Glycolysis Pathway Activity

4 Insights on

• Reduced Energy Intake
• Increased Postprandial Energy Expenditure
• Decreased Lower Respiratory Quotient
• Reduced Preoccupation with Food

1 Insight on

• Reduced Listeria monocytogenes Growth

3 Insights on

• Altered Microbial Profile
• Increased Bcoa191 Counts
• Decreased Clit135 Counts

2 Insights on

• Reduced Enteropathogenic Infection Risk
• Improved Intestinal Defense

19 Insights on

• Improved Gut Microbiota
• Increased Bifidobacteria Levels
• Increased Short-Chain Fatty Acid Production
• Increased Microbial Diversity
• Elevated Bifidobacterium Levels
• Absence of Adverse Effects
• Increased Short Chain Fatty Acids
• Safety of Consumption
• Improved Safe Consumption Practices
• Modified Fecal Microbiota
• Increased Bifidobacterial Population
• Improved Bifidobacteria Levels
• Modulated Gut Microbiota
• Improved Microbial Diversity
• Increased Bifidobacterium Levels
• Increased SCFA Production
• Safe Administration
• Increased SCFA Concentration
• Altered Short-Chain Fatty Acid Production

3 Insights on

• Reduced Occurrence of Necrotizing Enterocolitis
• Reduced Occurrence of NEC (Bell's Stage 2 or Higher)
• Probiotic Adherence Variability Based on Host Factors

4 Insights on

• Reduced Salmonella Incidence
• Reduced Intestinal Cell Adhesion
• Maintained Cellular Viability Post Spray Drying
• Preserved Membrane Integrity

3 Insights on

• Enhanced Disease Resistance
• Enhanced Immune Response
• Improved Growth

11 Insights on

• Increased Adverse Events
• Increased Abundance of Lactobacillus Crispatus
• Safety of Lactobacillus crispatus Consumption
• Acceptability of Lactobacillus crispatus
• Colonization with Lactobacillus Crispatus
• Safety in Treatment for Bacterial Vaginosis
• Bacterial Vaginosis Colonization
• Reduced Genitourinary Discomfort
• Absence of Deep Epithelial Disruption
• Safety in Terms of Adverse Events
• Genitourinary Adverse Events

3 Insights on

• Enhanced Disease Resistance
• Improved Cellular Immune Response
• Improved Immunity Status

3 Insights on

• Improved Amino Acid Absorption
• Enhanced Protein Kinase C Activity
• Improved Protein Kinase C Activity

4 Insights on

• Increased Regulatory T Cell Count
• Increased CD8+ T Cells
• Improved Natural Killer Cell Activation
• Increased Activation of Regulatory T Cells

2 Insights on

• Increased Bifidobacteria Growth
• Enhanced Xylo-oligosaccharide Utilization

2 Insights on

• Prevention of Necrotising Enterocolitis
• Reduced Intestinal Apoptosis

6 Insights on

• Increased Fecal Lactobacilli
• Increased Fecal Butyrate Levels
• No Adverse Health Effects
• Increased Fecal Butyric Acid Concentration
• Increased Fecal Lactobacilli Content
• Presence of Lactobacillus salivarius CECT5713 in Feces

2 Insights on

• Improved Immune Response
• Enhanced Disease Resistance

5 Insights on

• Reduced Frequency of Defecation
• Reduced Watery Stools
• Increased Organic Acid Levels
• Improved Stool Quality
• Increased Intrinsic Bifidobacteria Levels

5 Insights on

• Increased PMN Cell Phagocytic Capacity
• Increased Serum Lysozyme Activity
• Elevated Serum IgM Levels
• Improved Phagocytic Activity
• Elevated Complement C3 Levels

4 Insights on

• Reduced Intestinal Inflammation
• Reduced Gut Inflammation
• Reduced Inflammation
• Reduced Intestinal Histological Damage

6 Insights on

• Reduced Inflammatory Response
• Improved Immunomodulation
• Reduced Inflammation
• Enhanced Immunomodulatory Function
• Enhanced Anti-Infective Properties
• Improved Anti-infection Response

9 Insights on

• Reduced Incidence of Common Infectious Diseases
• Reduced Proportion of Volunteers with At Least One CID
• Delayed Occurrence of CID
• Reduced Incidence of Chronic Inflammatory Diseases in Smokers
• Reduced Fever Duration During CID
• Reduced Fever Duration
• Reduced Incidence of Common Infections
• Delayed Onset of Infection
• Reduced Cumulative Incidents of CIDs in Smokers

3 Insights on

• Improved Growth Performance
• Increased Protease Activity
• Increased Serum Amylase Activity

3 Insights on

• Increased Production of Bioactive Peptides with Angiotensin Converting Enzyme Inhibitory Activity
• Reduced Hypertension
• Increased Production of Bioactive Peptides

5 Insights on

• Improved Bowel Movement Frequency
• Improved Stool Consistency
• Increased Bowel Movement Frequency
• Reduced Inconsolable Crying Episodes
• No Adverse Health Effects

3 Insights on

• Reduced Body Weight
• Reduced Body Fat Mass
• Reduced Weight Gain